查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128024

心肌肌鈣蛋白市場：規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測

Cardiac Troponin Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

心肌肌鈣蛋白市場成長要素

2025年全球心肌肌鈣蛋白市場規模為35億美元，預計將從2026年的37.8億美元成長至2034年的71.7億美元，預測期內複合年成長率（CAGR）為8.30%。北美地區在全球心肌肌鈣蛋白市場中佔主導地位，2025年市場佔有率達到41.15%，這主要得益於先進心臟診斷技術的普及、心血管疾病患病率的上升以及有利的保險報銷政策。

心肌肌鈣蛋白是一種檢測心肌損傷，特別是心肌梗塞（心臟病發作）的黃金標準生物標記。肌鈣蛋白I (cTnI) 和肌鈣蛋白T (cTnT) 是心肌細胞受損後釋放到血液中的高度特異性蛋白質。快速且準確地測量這些生物標記有助於醫生早期診斷急性冠狀動脈症候群(ACS)，從而及時治療並改善患者預後。心血管疾病負擔日益加重、老年人口不斷成長、高靈敏度檢測技術的進步以及即時檢測的普及，持續推動全球市場成長。

心血管疾病負擔日益加重，推動了市場擴張。

心血管疾病發生率的不斷上升仍然是心肌肌鈣蛋白市場的主要成長要素。在人口老化、缺乏運動、肥胖、糖尿病和高血壓等因素的背景下，心肌梗塞、冠狀動脈疾病、鬱血性心臟衰竭和急性冠狀動脈症候群在全球範圍內持續增加。

公共衛生統計數據顯示，心臟病仍然是全球主要死因之一，這顯著增加了對快速診斷生物標記的需求。高靈敏度心肌肌鈣蛋白檢測徹底改變了急診醫學中的心臟診斷，使得在症狀出現後數小時內即可檢測到輕微的心肌損傷。

此外，急診室擴大採用即時診斷（POC）系統，使醫護人員能夠更快地獲得結果，改善治療決策，並縮短住院時間。

市場趨勢

影響市場格局的最重要趨勢之一是高靈敏度心肌肌鈣蛋白 (hs-cTn)檢測法和即時檢測技術的日益普及。與傳統的實驗室檢測相比，這些技術能夠更快、更準確地檢測出心肌損傷。

醫療機構正擴大在急診室、救護車和偏遠醫療機構部署攜帶式診斷設備。持續的產品創新、分析靈敏度的提高、人工智慧輔助的解讀以及自動化，進一步增強了心肌肌鈣蛋白檢測在心血管疾病管理中的作用。

市場促進因素

隨著心血管疾病發生率的不斷上升，對心臟生物標記檢測的需求依然強勁。早期診斷對於降低心肌梗塞和急性冠狀動脈症候群相關的死亡率仍然至關重要。

另一個主要的成長要素是領先企業不斷推出技術先進的診斷產品。這些企業正在開發高靈敏度的檢測方法，能夠更準確地檢測出極低濃度的肌鈣蛋白，從而實現早期干預，改善患者預後。

此外，隨著老年人口的增加，預計未來幾年心血管疾病的診斷數量將大幅上升，從而對心肌肌鈣蛋白檢測產生持續的需求。

市場限制因素

儘管成長前景強勁，但仍有一些阻礙因素阻礙市場擴張。傳統的肌鈣蛋白檢測法在心肌梗塞發生後的最初幾小時內往往靈敏度不足，限制了診斷準確性。

雖然高靈敏度的檢測方法可以解決許多此類問題，但從傳統檢測系統過渡到高靈敏度檢測系統需要大量投資，尤其是在開發中國家，需要在檢查室基礎設施建設、設備升級和醫療保健專業人員培訓等領域進行投資。

市場機遇

醫療保健基礎設施投資的增加、緊急診斷服務的加強以及攜帶式即時檢測系統的日益普及，為市場相關人員帶來了巨大的機會。

在亞太、拉丁美洲和中東等新興經濟體，醫療保健正變得越來越現代化，這為製造商提供了擴大產品系列和加強分銷網路的機會。

此外，持續進行的旨在提高生物標記靈敏度和將人工智慧整合到診斷平台的研究，預計將在預測期內帶來新的成長機會。

區域分析

預計北美將引領全球市場，2025年市場規模將達14.4億美元，2026年將達15.6億美元。完善的醫療保健基礎設施、心血管疾病盛行率的上升、有利的報銷機制以及高靈敏度診斷方法的快速普及，持續推動該地區的成長。預計美國市場規模將在2026年達到14億美元。

預計到 2025 年，歐洲市場規模將達到 9.2 億美元，到 2026 年將達到 9.9 億美元。 CE 標誌診斷產品的廣泛應用、主要製造商的進入以及高靈敏度檢測方法的日益普及，都推動了該地區市場的擴張。

預計亞太地區市場規模將在2025年達到7.4億美元，2026年達到8億美元，成為成長最快的區域市場。心血管疾病負擔日益加重、醫療基礎設施不斷完善、公眾意識不斷提高以及新產品的上市，持續推動中國、日本和印度市場的成長。

由於醫療設施的改善、診斷能力的提高以及政府對心血管疾病管理投入的增加，拉丁美洲、中東和非洲地區也經歷了穩定成長。

近期行業趨勢包括新的高靈敏度檢測方法、品管解決方案、用於免疫檢測的創新抗體以及擴大監管批准，所有這些都旨在提高診斷性能並增強競爭力。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要心血管疾病盛行率：依主要國家分類，2024/2025 年
  • 心肌肌鈣蛋白檢測的技術進步
  • 知名公司推出新產品。
  • 產業重大發展動態（合併、收購、合作等）
  • 新冠疫情對市場的影響

第5章：2021-2034年全球心肌肌鈣蛋白市場分析、洞察與預測

  • 市場分析、洞察與預測：按類型
    • 肌鈣蛋白T
    • 肌鈣蛋白 I
  • 市場分析、洞察與預測：按設施類型分類
    • 臨床試驗
    • 即時偵測 (POC)
  • 市場分析、洞察與預測：按指標
    • 心肌梗塞
    • 鬱血性心臟衰竭
    • 急性冠狀動脈症候群
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院和診所
    • 診斷檢查室
    • 居家醫療環境及其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美心臟肌鈣蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲心臟肌鈣蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家

第8章：亞太地區心肌肌鈣蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲心肌肌鈣蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲心臟肌鈣蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
    • bioMerieux SA
    • Abbott
    • Siemens Healthineers AG
    • Eurolyser Diagnostica GmbH
    • QuidelOrtho（Quidel Corporation）
    • PerkinElmer Inc.
    • Beckman Coulter, Inc.（Danaher）
    • RESPONSE BIOMEDICAL
    • LifeSign LLC.
Product Code: FBI101234

Growth Factors of cardiac troponin Market

The global cardiac troponin market was valued at USD 3.50 billion in 2025 and is projected to grow from USD 3.78 billion in 2026 to USD 7.17 billion by 2034, exhibiting a CAGR of 8.30% during the forecast period. North America dominated the global cardiac troponin market with a 41.15% market share in 2025, supported by the widespread adoption of advanced cardiac diagnostics, increasing cardiovascular disease prevalence, and favorable reimbursement policies.

Cardiac troponin is the gold-standard biomarker used to detect cardiac muscle injury, particularly myocardial infarction (heart attack). Troponin I (cTnI) and Troponin T (cTnT) are highly specific proteins released into the bloodstream following damage to heart muscle cells. Rapid and accurate measurement of these biomarkers enables physicians to diagnose acute coronary syndrome (ACS) at an early stage, allowing timely treatment and improving patient outcomes. The growing burden of cardiovascular diseases, increasing geriatric population, technological advancements in high-sensitivity assays, and expanding adoption of point-of-care testing continue to drive market growth worldwide.

Rising Cardiovascular Disease Burden Drives Market Expansion

The increasing incidence of cardiovascular disorders remains the primary growth driver for the cardiac troponin market. Heart attacks, coronary artery disease, congestive heart failure, and acute coronary syndrome continue to increase globally due to aging populations, sedentary lifestyles, obesity, diabetes, and hypertension.

According to public health statistics, heart disease remains one of the leading causes of mortality worldwide, significantly increasing demand for rapid diagnostic biomarkers. High-sensitivity cardiac troponin assays have transformed emergency cardiac diagnosis by enabling clinicians to detect even minor myocardial injury within a few hours of symptom onset.

Additionally, the growing adoption of point-of-care (POC) diagnostic systems in emergency departments allows healthcare professionals to obtain faster results, improving treatment decisions and reducing hospital admission times.

Market Trends

One of the most important trends shaping the market is the increasing adoption of high-sensitivity cardiac troponin (hs-cTn) assays and point-of-care testing. These technologies provide faster, more accurate detection of myocardial injury compared to conventional laboratory assays.

Healthcare providers are increasingly integrating portable diagnostic devices into emergency rooms, ambulances, and remote healthcare facilities. Continuous product innovation, improved analytical sensitivity, AI-assisted interpretation, and automation are further strengthening the role of cardiac troponin testing in cardiovascular disease management.

Market Drivers

The growing prevalence of cardiovascular diseases continues to create strong demand for cardiac biomarker testing. Early diagnosis remains essential for reducing mortality associated with myocardial infarction and acute coronary syndrome.

Another major growth factor is the continuous introduction of technologically advanced diagnostic products by leading manufacturers. Companies are developing high-sensitivity assays capable of detecting extremely low concentrations of troponin with greater precision, enabling earlier intervention and improved patient outcomes.

Furthermore, the expanding elderly population is expected to significantly increase the number of cardiovascular diagnostic procedures over the coming years, creating sustained demand for cardiac troponin testing.

Market Restraints

Despite strong growth prospects, certain limitations continue to affect market expansion. Conventional cardiac troponin assays often lack sufficient sensitivity during the very early hours following myocardial infarction, limiting their diagnostic accuracy.

Although high-sensitivity assays have addressed many of these concerns, the transition from conventional testing systems requires substantial investment in laboratory infrastructure, equipment upgrades, and healthcare professional training, particularly in developing economies.

Market Opportunities

Growing investments in healthcare infrastructure, expanding emergency diagnostic services, and increasing availability of portable point-of-care testing systems present significant opportunities for market players.

Emerging economies across Asia Pacific, Latin America, and the Middle East are witnessing increasing healthcare modernization, providing manufacturers with opportunities to expand their product portfolios and strengthen distribution networks.

Furthermore, continuous research focused on improving biomarker sensitivity and integrating artificial intelligence into diagnostic platforms is expected to unlock new growth opportunities throughout the forecast period.

Segment Analysis

By Type

The Troponin I segment is projected to dominate the global market with a 73.32% market share in 2026. Troponin I remains the preferred biomarker due to its high specificity for myocardial infarction and growing availability of advanced high-sensitivity and point-of-care testing systems.

Meanwhile, the Troponin T segment is expected to witness strong growth, supported by increasing regulatory approvals, broader clinical adoption, and expanding use in early heart failure diagnosis.

By Setting

The laboratory testing segment is expected to account for 73.68% of the global market in 2026 owing to its superior analytical precision and widespread use in hospital laboratories.

The point-of-care testing segment is anticipated to record the fastest growth during the forecast period due to increasing use in emergency departments, ambulances, and resource-limited healthcare settings where rapid diagnosis is essential.

By Indication

The acute coronary syndrome (ACS) segment is expected to dominate the market with a 55.15% share in 2026. Rising cases of ACS worldwide continue to drive demand for rapid troponin testing for emergency diagnosis and patient triage.

Myocardial infarction remains another major application area, supported by the growing elderly population and increasing prevalence of heart attacks globally.

By End User

The hospitals & clinics segment is projected to hold the largest 63.44% market share in 2026. High patient admissions, increasing cardiovascular emergencies, and widespread adoption of advanced diagnostic assays contribute to segment dominance.

Diagnostic laboratories are also expected to witness healthy growth due to increasing outsourcing of cardiac testing services and expanding laboratory infrastructure.

Regional Analysis

North America dominated the global market with a value of USD 1.44 billion in 2025 and is projected to reach USD 1.56 billion in 2026. Strong healthcare infrastructure, rising cardiovascular disease prevalence, favorable reimbursement systems, and rapid adoption of high-sensitivity assays continue to drive regional growth. The U.S. market is projected to reach USD 1.40 billion in 2026.

Europe accounted for USD 0.92 billion in 2025 and is expected to reach USD 0.99 billion in 2026. Broad adoption of CE-marked diagnostic products, presence of major manufacturers, and increasing use of high-sensitivity assays support regional expansion.

Asia Pacific generated USD 0.74 billion in 2025 and is projected to grow to USD 0.80 billion in 2026, making it the fastest-growing regional market. Increasing cardiovascular disease burden, expanding healthcare infrastructure, growing awareness, and new product launches continue to fuel market growth across China, Japan, and India.

Latin America and the Middle East & Africa are also experiencing steady growth due to improving healthcare facilities, expanding diagnostic capabilities, and increasing government investments in cardiovascular disease management.

Competitive Landscape

The global cardiac troponin market remains moderately competitive, with several multinational diagnostic companies investing heavily in product innovation, regulatory approvals, and strategic collaborations.

Leading market participants include F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthineers AG, bioMerieux SA, Beckman Coulter, QuidelOrtho, Eurolyser Diagnostica GmbH, PerkinElmer Inc., RESPONSE BIOMEDICAL, and LifeSign LLC.

Recent industry developments include new high-sensitivity assays, quality control solutions, innovative antibodies for immunoassays, and expanded regulatory approvals designed to improve diagnostic performance and strengthen competitive positioning.

Conclusion

The global cardiac troponin market is expected to experience robust growth through 2034, driven by the rising prevalence of cardiovascular diseases, increasing adoption of high-sensitivity diagnostic assays, and expanding use of point-of-care testing in emergency medicine. Technological advancements, continuous product innovation, and growing healthcare investments are improving diagnostic accuracy and patient outcomes worldwide. Although conventional assay limitations and infrastructure costs remain challenges, increasing awareness of early cardiac diagnosis, expanding healthcare access, and ongoing innovations in biomarker technology are expected to sustain long-term market growth.

Segmentation

By Type

  • Troponin T
  • Troponin I

By Setting

  • Laboratory Testing
  • Point-of-Care (POC) Testing

By Indication

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Others

By End User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Homecare Settings & Others

By Region

  • North America ( By Type, By Setting, By Indication, By End User, By Country)
    • U.S.
    • Canada
  • Europe ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries/Regions, 2024/2025
  • 4.2. Technological Advancements in Cardiac Troponin Testing
  • 4.3. New Product Launches. By Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Troponin T
    • 5.1.2. Troponin I
  • 5.2. Market Analysis, Insights and Forecast - By Setting
    • 5.2.1. Laboratory Testing
    • 5.2.2. Point-of-Care (POC) Testing
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Myocardial Infarction
    • 5.3.2. Congestive Heart Failure
    • 5.3.3. Acute Coronary Syndrome
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By End-User
    • 5.4.1. Hospitals & Clinics
    • 5.4.2. Diagnostic Laboratories
    • 5.4.3. Homecare Settings & Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Troponin T
    • 6.1.2. Troponin I
  • 6.2. Market Analysis, Insights and Forecast - By Setting
    • 6.2.1. Laboratory Testing
    • 6.2.2. Point-of-Care (POC) Testing
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Myocardial Infarction
    • 6.3.2. Congestive Heart Failure
    • 6.3.3. Acute Coronary Syndrome
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By End-User
    • 6.4.1. Hospitals & Clinics
    • 6.4.2. Diagnostic Laboratories
    • 6.4.3. Homecare Settings & Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Troponin T
    • 7.1.2. Troponin I
  • 7.2. Market Analysis, Insights and Forecast - By Setting
    • 7.2.1. Laboratory Testing
    • 7.2.2. Point-of-Care (POC) Testing
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Myocardial Infarction
    • 7.3.2. Congestive Heart Failure
    • 7.3.3. Acute Coronary Syndrome
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By End-User
    • 7.4.1. Hospitals & Clinics
    • 7.4.2. Diagnostic Laboratories
    • 7.4.3. Homecare Settings & Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Rest of Europe

8. Asia Pacific Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Troponin T
    • 8.1.2. Troponin I
  • 8.2. Market Analysis, Insights and Forecast - By Setting
    • 8.2.1. Laboratory Testing
    • 8.2.2. Point-of-Care (POC) Testing
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Myocardial Infarction
    • 8.3.2. Congestive Heart Failure
    • 8.3.3. Acute Coronary Syndrome
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By End-User
    • 8.4.1. Hospitals & Clinics
    • 8.4.2. Diagnostic Laboratories
    • 8.4.3. Homecare Settings & Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. China
    • 8.5.2. India
    • 8.5.3. Japan
    • 8.5.4. Australia
    • 8.5.5. Rest of Asia Pacific

9. Latin America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Troponin T
    • 9.1.2. Troponin I
  • 9.2. Market Analysis, Insights and Forecast - By Setting
    • 9.2.1. Laboratory Testing
    • 9.2.2. Point-of-Care (POC) Testing
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Myocardial Infarction
    • 9.3.2. Congestive Heart Failure
    • 9.3.3. Acute Coronary Syndrome
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By End-User
    • 9.4.1. Hospitals & Clinics
    • 9.4.2. Diagnostic Laboratories
    • 9.4.3. Homecare Settings & Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Troponin T
    • 10.1.2. Troponin I
  • 10.2. Market Analysis, Insights and Forecast - By Setting
    • 10.2.1. Laboratory Testing
    • 10.2.2. Point-of-Care (POC) Testing
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Myocardial Infarction
    • 10.3.2. Congestive Heart Failure
    • 10.3.3. Acute Coronary Syndrome
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By End-User
    • 10.4.1. Hospitals & Clinics
    • 10.4.2. Diagnostic Laboratories
    • 10.4.3. Homecare Settings & Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. bioMerieux SA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Abbott
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Siemens Healthineers AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Eurolyser Diagnostica GmbH
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. QuidelOrtho (Quidel Corporation)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. PerkinElmer Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Beckman Coulter, Inc. (Danaher)
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. RESPONSE BIOMEDICAL
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. LifeSign LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 3: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 4: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 5: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 8: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 9: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 10: North America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 13: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 14: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 15: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 18: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 20: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 23: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 24: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 25: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 27: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 28: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 30: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cardiac Troponin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cardiac Troponin Market Value Share (%), By Type, 2025 & 2034
  • Figure 3: Global Cardiac Troponin Market Value Share (%), by Setting, 2025 & 2034
  • Figure 4: Global Cardiac Troponin Market Value Share (%), by Indication, 2025 & 2034
  • Figure 5: Global Cardiac Troponin Market Value Share (%), by End-User, 2025 & 2034
  • Figure 6: Global Cardiac Troponin Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 8: North America Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 9: North America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 10: North America Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 11: North America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 12: North America Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 13: North America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 14: North America Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 15: North America Cardiac Troponin Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Cardiac Troponin Market Value Share (%), By Country, 2025
  • Figure 17: Europe Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 18: Europe Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 19: Europe Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 20: Europe Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 21: Europe Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 22: Europe Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 23: Europe Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 24: Europe Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 25: Europe Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 28: Asia Pacific Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 29: Asia Pacific Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 30: Asia Pacific Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 31: Asia Pacific Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 32: Asia Pacific Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 33: Asia Pacific Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 34: Asia Pacific Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 35: Asia Pacific Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 38: Latin America Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 39: Latin America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 40: Latin America Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 41: Latin America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 42: Latin America Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 43: Latin America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 44: Latin America Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 45: Latin America Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 48: Middle East & Africa Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 49: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 50: Middle East & Africa Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 51: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 53: Middle East & Africa Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 54: Middle East & Africa Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 55: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034s
  • Figure 56: Middle East & Africa Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Cardiac Troponin Market Share (%), By Company, 2025